Search and analyze individual stocks with comprehensive metrics
Nath Bio-Genes (India) Limited
Fundamental Score
Nath Bio-Genes (India) Limited Share Price & Market Analysis
Profitability Metrics
Return on Equity
Return on Capital Employed
Operating Profit Margin (5Y)
Dividend Yield
Valuation Metrics
Price to Earnings
Market Capitalization
Industry P/E
Growth Metrics
YoY Quarterly Profit Growth
YoY Quarterly Sales Growth
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Financial Health
Debt to Equity
Interest Coverage
Free Cash Flow (5Y)
Ownership Structure
Promoter Holding
FII Holding
DII Holding
Pledged Percentage
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Market Data Analysis & Educational Insights
Educational evaluation of NATHBIOGEN across key market metrics for learning purposes.
Positive Indicators
5 factors identified
Strong Operating Margins (20.59%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages. This indicates sustainable profitability potential.
Attractive Valuation (P/E: 7.12 vs Industry: 20.60)
Observation: Trading at discount to industry peers.
Analysis: P/E below industry average may present value opportunity if fundamentals support the business case.
Conservative Debt Levels (D/E: 0.17)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns and flexibility for growth investments.
Strong Interest Coverage (5.68x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk and strong debt servicing capability.
Strong Cash Generation (₹108.69 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Risk Factors
7 factors identified
Below-Average Return on Equity (6.77%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (7.35%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation. Review business model and competitive positioning.
Limited Growth History (1.50% CAGR)
Observation: Below-average 5-year sales growth trajectory.
Analysis: Low sales CAGR may indicate mature markets or limited growth opportunities. Assess future growth catalysts.
Weak Earnings Growth (-3.32% CAGR)
Observation: Below-average 5-year EPS growth performance.
Analysis: Low EPS growth may not keep pace with inflation. Consider growth catalysts and competitive positioning.
Stagnant Profit Growth (-3.32% CAGR)
Observation: Limited 5-year profit growth trajectory.
Analysis: Low profit growth may indicate scalability challenges or market maturity. Assess transformation initiatives.
Limited Institutional Interest (FII+DII: 2.66%)
Observation: Low institutional participation may affect liquidity and visibility.
Analysis: Limited institutional interest may indicate size constraints or visibility issues in the investment community.
Small Market Cap
Observation: Higher investment risk due to limited size.
Analysis: Small-cap stocks typically carry higher volatility and liquidity risks.
📊 Educational Market Overview
Disclaimer: The ratings and scores are generated algorithmically from publicly available market data and are provided for educational and informational purposes only. They do not constitute investment advice, recommendation, or solicitation to buy/sell any securities.
Loading Peer Comparison
Finding companies in the Other Agricultural Products sector...
Financial Statements
Comprehensive financial data for Nath Bio-Genes (India) Limited
About NATHBIOGEN
Company Details
Market Information
Performance
NATHBIOGEN Stock Details & Analysis
Key Financial Metrics
Growth & Valuation
Frequently Asked Questions
What is the current price of NATHBIOGEN?
NATHBIOGEN is currently trading at ₹168.95 with a gain of 0.00% today. The current market price (CMP) represents the last traded price of NATHBIOGEN shares on the stock exchange. This price fluctuates throughout trading hours based on supply and demand. You can track real-time price movements, percentage changes, and trading volume in the header section.
What is the P/E ratio of NATHBIOGEN and what does it mean?
NATHBIOGEN has a P/E ratio of 7.12x compared to the industry average of 20.60x. The Price-to-Earnings (P/E) ratio is calculated by dividing the current share price by earnings per share (EPS). This means investors are paying ₹7 for every ₹1 of annual earnings. This is lower than the industry average, which might indicate undervaluation or slower growth expectations.
How is NATHBIOGEN performing according to Bull Run's analysis?
NATHBIOGEN has a Bull Run fundamental score of 39.9/100, which indicates concerns that require careful analysis. This comprehensive rating is based on 15+ financial parameters including profitability (ROE: 6.77%), growth metrics, valuation ratios, and financial health indicators. The score updates quarterly with new financial data and helps you quickly assess overall investment quality.
What sector and industry does NATHBIOGEN belong to?
NATHBIOGEN operates in the Agricultural Food & other Products industry. This sector classification helps understand the broader economic trends, regulatory framework, and competitive landscape affecting Nath Bio-Genes (India) Limited. Companies in this industry typically face similar market dynamics, cyclical patterns, and macroeconomic factors. Understanding the industry context is crucial for peer comparison and assessing how sector-specific trends might impact the stock's performance.
What is Return on Equity (ROE) and why is it important for NATHBIOGEN?
NATHBIOGEN has an ROE of 6.77%, which suggests challenges in generating returns from shareholders' equity. Return on Equity measures how efficiently Nath Bio-Genes (India) Limited generates profits from shareholders' equity. An ROE of 7% means the company generates ₹7 profit for every ₹100 of shareholders' equity. This metric is crucial for assessing management's ability to create value for shareholders.
How is NATHBIOGEN's debt-to-equity ratio and what does it indicate?
NATHBIOGEN has a debt-to-equity ratio of 0.17, which indicates conservative financing with low financial risk. This means the company has ₹17 of debt for every ₹100 of equity. This conservative approach provides financial stability but may limit growth potential.
What is NATHBIOGEN's dividend yield and is it a good dividend stock?
NATHBIOGEN offers a dividend yield of 1.17%, which means you receive ₹1.17 annual dividend for every ₹100 invested. The focus appears to be more on growth rather than dividend income. Dividend yield is calculated as annual dividend per share ÷ current share price × 100. Evaluate dividend consistency over 5+ years and free cash flow coverage for sustainability.
How has NATHBIOGEN grown over the past 5 years?
NATHBIOGEN has achieved 5-year growth rates of: Sales Growth 1.50%, Profit Growth -3.32%, and EPS Growth -3.32%. These growth metrics show the company's ability to expand its business and improve profitability over time. Sales growth indicates market expansion, profit growth shows operational efficiency, and EPS growth directly impacts share price appreciation potential.
What is the promoter holding in NATHBIOGEN and why does it matter?
Promoters hold 45.59% of NATHBIOGEN shares, with 13.78% of promoter shares pledged. This promoter holding level suggests balanced ownership between management and public shareholders. Low pledging indicates financial stability of promoters. Recent change in promoter holding: -0.01%.
How does NATHBIOGEN compare with its industry peers?
NATHBIOGEN trades at P/E 7.12x vs industry average 20.60x, with ROE of 6.77% and ROCE of 7.35%. The stock appears undervalued relative to peers based on P/E ratio. Peer comparison helps identify whether NATHBIOGEN is outperforming its competitive set in profitability, growth, and valuation metrics.
What is NATHBIOGEN's market capitalization and what category does it fall into?
NATHBIOGEN has a market capitalization of ₹326 crores, making it a Large-cap stock. Large-cap stocks offer stability and liquidity but typically slower growth. Market cap is calculated as current share price × total outstanding shares, representing the company's total market value.
What are the key financial ratios to consider for NATHBIOGEN?
Key ratios for NATHBIOGEN: ROE 6.77% (Needs improvement), ROCE 7.35%, P/E 7.12x, Debt-to-Equity 0.17, Interest Coverage 5.68x. These ratios help assess profitability (ROE, ROCE), valuation (P/E), financial health (D/E, Interest Coverage), and overall investment quality. Compare these with industry medians and historical trends for meaningful analysis.
How volatile is NATHBIOGEN stock and what is its beta?
NATHBIOGEN has a beta of N/A, which means it is less volatile than the market and offers defensive characteristics. Beta measures price volatility relative to the Nifty 50. Lower beta stocks provide stability during uncertain market conditions. Consider beta alongside your risk tolerance and portfolio diversification strategy.
What is the 52-week high and low for NATHBIOGEN?
NATHBIOGEN has a 52-week high of ₹N/A and low of ₹N/A. Currently trading at ₹168.95, the stock is within its annual trading range. Trading near highs indicates strong momentum but limited upside potential.
What are the key risks associated with investing in NATHBIOGEN?
Key risks for NATHBIOGEN include: Market volatility (Beta: N/A), financial leverage (Debt-to-Equity: 0.17), and operational challenges. The stock has a Fundamental Score of 39.9/100, indicating higher risk requiring thorough due diligence. Sector-specific risks in Agricultural Food & other Products include regulatory changes, economic cycles, and competitive pressures. Consider your risk tolerance, investment horizon, and portfolio diversification before investing. Past performance doesn't guarantee future results.
What is NATHBIOGEN's operating profit margin and how has it trended?
NATHBIOGEN has a 5-year average Operating Profit Margin (OPM) of 20.59%, which is excellent and indicates strong pricing power and cost control. Operating Profit Margin shows operational efficiency by measuring operating profit as a percentage of revenue. This strong margin indicates competitive advantages and operational leverage. Compare with industry peers to understand relative performance.
How is NATHBIOGEN's quarterly performance in terms of sales and profit growth?
NATHBIOGEN's recent quarterly performance shows YoY Sales Growth of 14.88% and YoY Profit Growth of 6.67%. This shows decent growth momentum in the business. Sales growth shows market demand while profit growth reveals operational efficiency and margin management.
What is the FII and DII holding pattern in NATHBIOGEN?
NATHBIOGEN has FII holding of 0.41% and DII holding of 2.25%, totaling 2.66% institutional ownership. This institutional participation level shows the confidence of professional money managers. Monitor quarterly changes in institutional holdings for investment flow trends and sentiment.